| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.4 | 0.6 | 1.5 |
| Total income | 0.4 | 0.6 | 1.5 |
| Profit before exceptional items & tax | 0.2 | -0.4 | 1.3 |
| Profit before tax | 0.2 | -0.4 | 1.3 |
| Net profit | 0.2 | -0.4 | 1.3 |
| Operating margin | 50.0% | -66.7% | 86.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -84.60% |
|---|---|
| Revenue, year on year | -73.30% |
BSE results filing, NSE: SUNTECHNO. Figures extracted from the filing.
Biogen Pharmachem Industries Ltd: key numbers
- Share price
- ₹0.28
- Market cap
- ₹29.49 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.86 Cr
- P/E (TTM)
- -177.2×Sector 22.0×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biogen Pharmachem Industries Ltd
All →Biogen Pharmachem Industries Annual Report
Biogen Pharmachem Industries Limited submitted its 31st Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 29, 2026.
Biogen Pharmachem Industries Annual General Meeting
Biogen Pharmachem Industries Ltd has issued a notice for its 31st Annual General Meeting scheduled for September 29, 2026. The meeting will be held via video conferencing.
Biogen Pharmachem Industries Q4 FY26 Results: Net Loss of ₹0.4 Cr
Biogen Pharmachem Industries Ltd reported revenue from operations of ₹0.6 Cr (-57.1% YoY) and a net loss of ₹0.4 Cr for Q4 FY26.
- Key figure
- Net loss ₹0.4 Cr